UB Paderborn / Katalog / Suche / in CDI

Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens

Current opinion in pharmacology, 2020-10, Vol.54, p.179-187

2020

Volltextzugriff (PDF)

The Journey of HIV‑1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic

Journal of medicinal chemistry, 2019-05, Vol.62 (10), p.4851-4883

2019

Volltextzugriff (PDF)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis

Diseases, 2023-10, Vol.11 (4), p.146

2023

Volltextzugriff (PDF)

Untargeted Metabolomics Based Prediction of Therapeutic Potential for Apigenin and Chrysin

International journal of molecular sciences, 2023-02, Vol.24 (4), p.4066

2023

Volltextzugriff (PDF)

Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis

Cancers, 2024-03, Vol.16 (6), p.1188

2024

Volltextzugriff (PDF)

Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I

Anti-cancer agents in medicinal chemistry, 2007-09, Vol.7 (5), p.524

2007

Volltextzugriff (PDF)

Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II

Anti-cancer agents in medicinal chemistry, 2008-02, Vol.8 (2), p.205

2008

Volltextzugriff (PDF)

Design, synthesis and biological activity of N4-phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase

Journal of enzyme inhibition and medicinal chemistry, 2018-01, Vol.33 (1), p.74-84

2018

Volltextzugriff (PDF)

Abstract 5337: Design, synthesis and evaluation of dual-targeted mEGFR and AURK inhibitors as anticancer agents

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.5337-5337

2023

Volltextzugriff (PDF)

Three-Dimensional Visualization of Kinase Inhibitors as Therapeutically Relevant Examples To Reinforce Types of Enzyme Inhibitors

Journal of chemical education, 2019-02, Vol.96 (2), p.296-303

2019

Volltextzugriff (PDF)

Design, synthesis, and evaluation of dual EGFR/AURKB inhibitors as anticancer agents for non-small cell lung cancer

Bioorganic & medicinal chemistry letters, 2024-03, Vol.100, p.129612-129612, Article 129612

2024

Volltextzugriff (PDF)

A meta-analysis comparing therapeutic outcomes for anti-EGFR monotherapy to targeted therapy combinations for non-small cell lung cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21570-e21570

2020

Volltextzugriff (PDF)

A Team‐based Assignment to Integrate Basic Science and Pharmacotherapeutic Principles for Anticancer Agents

The FASEB journal, 2017-04, Vol.31 (S1)

2017

Volltextzugriff (PDF)

Abstract 589: A systematic review of randomized clinical trials for therapeutic outcomes of anti-EGFR agents used in combination with other targeted therapies

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.589-589

2018

Volltextzugriff (PDF)

Design, synthesis and biological activity of N 4 -phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase

Journal of enzyme inhibition and medicinal chemistry, 2018-12, Vol.33 (1), p.74

2018

Volltextzugriff (PDF)

A Team-based Assignment to Integrate Basic Science and Pharmacotherapeutic Principles for Anticancer Agents

American journal of pharmaceutical education, 2017-06, Vol.81 (5), p.93, Article 93

2017

Volltextzugriff (PDF)

Abstract 2800: Design, synthesis, selection, and evaluation of a potent multi-kinase targeting N 4-phenylsubstituted-7 H -pyrrolo[2,3- d ]pyrimidin-4-amine derivative with significant anticancer activity in P53 mutant and wild type models of upper gastrointestinal cancers

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.2800-2800

2018

Volltextzugriff (PDF)

A team-based assignment to integrate basic science and pharmacotherapeutic principles for anticancer agents

American journal of pharmaceutical education, 2017-06, Vol.81 (5), p.1

2017

Volltextzugriff (PDF)

Abstract 4180: RS-41, a multi-targeted kinase inhibitor, induces cell cycle arrest and apoptosis in p53 mutant and wild type models of upper gastrointestinal cancers

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4180-4180

2017

Volltextzugriff (PDF)

Abstract 5339: 4-Amino- N -phenylbenzamides as dual-targeted mEGFR and AURK inhibitors and anticancer agents

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.5339-5339

2023

Volltextzugriff (PDF)

Design, synthesis and biological activity of N 4 -phenylsubstituted-7 H -pyrrolo[2,3- d ]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase

Journal of enzyme inhibition and medicinal chemistry, 2018-01, Vol.33 (1), p.74-84

2018

Volltextzugriff (PDF)

Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents

Bioorganic & medicinal chemistry, 2010-05, Vol.18 (10), p.3575-3587

2010

Volltextzugriff (PDF)

N4-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4- diam ines as receptor tyrosine kinase inhibitors

Bioorganic & medicinal chemistry, 2012-01, Vol.20 (2), p.910-914

2012

Volltextzugriff (PDF)

N4-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors: Symposium-in-Print: Chemical Proteomics

Bioorganic & medicinal chemistry, 2012, Vol.20 (2), p.910-914

2012

Volltextzugriff (PDF)

N4-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors

Bioorganic & medicinal chemistry, 2012-01, Vol.20 (2), p.910-914

2012

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens

The Journey of HIV‑1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis

Untargeted Metabolomics Based Prediction of Therapeutic Potential for Apigenin and Chrysin

Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis

Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I

Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II

Design, synthesis and biological activity of N4-phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase

Abstract 5337: Design, synthesis and evaluation of dual-targeted mEGFR and AURK inhibitors as anticancer agents

Three-Dimensional Visualization of Kinase Inhibitors as Therapeutically Relevant Examples To Reinforce Types of Enzyme Inhibitors

Design, synthesis, and evaluation of dual EGFR/AURKB inhibitors as anticancer agents for non-small cell lung cancer

A meta-analysis comparing therapeutic outcomes for anti-EGFR monotherapy to targeted therapy combinations for non-small cell lung cancer

A Team‐based Assignment to Integrate Basic Science and Pharmacotherapeutic Principles for Anticancer Agents

Abstract 589: A systematic review of randomized clinical trials for therapeutic outcomes of anti-EGFR agents used in combination with other targeted therapies

Design, synthesis and biological activity of N 4 -phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase

A Team-based Assignment to Integrate Basic Science and Pharmacotherapeutic Principles for Anticancer Agents

Abstract 2800: Design, synthesis, selection, and evaluation of a potent multi-kinase targeting N 4-phenylsubstituted-7 H -pyrrolo[2,3- d ]pyrimidin-4-amine derivative with significant anticancer activity in P53 mutant and wild type models of upper gastrointestinal cancers

A team-based assignment to integrate basic science and pharmacotherapeutic principles for anticancer agents

Abstract 4180: RS-41, a multi-targeted kinase inhibitor, induces cell cycle arrest and apoptosis in p53 mutant and wild type models of upper gastrointestinal cancers

Abstract 5339: 4-Amino- N -phenylbenzamides as dual-targeted mEGFR and AURK inhibitors and anticancer agents

Design, synthesis and biological activity of N 4 -phenylsubstituted-7 H -pyrrolo[2,3- d ]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase

Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents

N4-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4- diam ines as receptor tyrosine kinase inhibitors

N4-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors: Symposium-in-Print: Chemical Proteomics

N4-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors

Suchergebnisse filtern